Poster Overview

Below is Excellergy’s AAAAI 2026 poster summarizing new pre-clinical data for Exl‑111, a trifunctional, rapid-acting monoclonal antibody designed to disable the IgE axis. The poster includes data across multiple pre-clinical systems evaluating (1) removal of receptor‑bound IgE from effector cells, (2) neutralization of free IgE, and (3) downregulation of FcεRI.

Download the full poster (PDF) for the complete figures, methods summary, and results.

Key Takeaways

This poster reports pre-clinical findings supporting Exl‑111’s ability to rapidly and durably impact the IgE/FcεRI pathway, including readouts relevant to allergic effector cell control.

Data presented include:

• Human whole blood assays evaluating removal of receptor‑bound IgE and basophil biomarker responses
• Biophysical studies assessing IgE dissociation dynamics
• Preclinical PK/PD studies evaluating durability of target engagement, free IgE suppression, and FcεRI modulation

These data help inform Exl‑111’s ongoing clinical development program, including the DISARM Phase 1 trial.

Media Coverage

Additional coverage and conversations about Excellergy and Exl‑111:

• Endpoints News — Excellergy debuts with $70M Series A and plan to take on Xolair
• San Francisco Business Times — Allergy-focused Palo Alto startup Excellergy scores $70 million (subscription may be required)
• BioPharma Dive — A young biotech nets $70M for a new type of allergy drug
• Allergic Living — Preventing Allergic Reactions by Disarming Anaphylaxis-Triggering Cells
• Scrip (Citeline) — Scrip Asks… What Does 2026 Hold for Biopharma? Part 4: R&D Innovation (featuring Todd Zavodnick)
• The BioHub Podcast (YouTube) — Can We “Switch Off” Allergies? Excellergy CEO on IgE, Immunology & Biotech Building – Todd Zavodnick